Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
about
Cost-effectiveness in managing skeletal related events in breast cancer: a strategy of less-intense dosing schedule of bone modifying agents.5-Hydroxy-4'-Nitro-7-Propionyloxy-Genistein Inhibited Invasion and Metastasis via Inactivating Wnt/b-Catenin Signal Pathway in Human Endometrial Carcinoma Ji Endometrial Cells.Efficacy and safety of de-escalation bone- modifying agents for cancer patients with bone metastases: a systematic review and meta-analysisOsteoporosis and musculoskeletal complications related to therapy of breast cancer
P2860
Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Cost-Effectiveness Analysis of ...... tases: CALGB 70604 (Alliance).
@en
Cost-Effectiveness Analysis of ...... tases: CALGB 70604 (Alliance).
@nl
type
label
Cost-Effectiveness Analysis of ...... tases: CALGB 70604 (Alliance).
@en
Cost-Effectiveness Analysis of ...... tases: CALGB 70604 (Alliance).
@nl
prefLabel
Cost-Effectiveness Analysis of ...... tases: CALGB 70604 (Alliance).
@en
Cost-Effectiveness Analysis of ...... tases: CALGB 70604 (Alliance).
@nl
P2093
P2860
P356
P1476
Cost-Effectiveness Analysis of ...... tases: CALGB 70604 (Alliance).
@en
P2093
Andrew L Himelstein
Bijan J Borah
Charles L Shapiro
James P Moriarty
Jared C Foster
Paul J Novotny
Stephen S Grubbs
P2860
P304
P356
10.1200/JCO.2017.73.7437
P407
P577
2017-10-12T00:00:00Z